Patents by Inventor Mark Hatcher

Mark Hatcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of nirogacestat
    Patent number: 12247012
    Abstract: The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: March 11, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • Synthesis of nirogacestat
    Patent number: 12234210
    Abstract: The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: February 25, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • Systems and methods for residual limbs of amputees
    Patent number: 12201536
    Abstract: Various aspects of this disclosure relate to a prosthetic cover comprising an array of sensors, which transmit signals to an array of electrodes in a liner that fits over a residual limb of an amputee. Different interactions with the prosthetic cover cause different activation of the electrodes to transmit electrical current through different areas of the residual limb and modulate neurons differently within the residual limb. Various aspects of this disclosure also relate to a prosthetic liner with a substrate that includes electrodes for transcutaneous electrical nerve stimulation and/or electronic muscle stimulation for a residual limb.
    Type: Grant
    Filed: June 10, 2024
    Date of Patent: January 21, 2025
    Assignee: JSG IP VENTURES, LLC
    Inventors: Jordan T. Doles, Michael Young, Paul Goudreau, Troy Winsand, Mark Hatcher
  • DOSAGE FORMS OF MIRDAMETINIB
    Publication number: 20240358661
    Abstract: The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
    Type: Application
    Filed: July 8, 2024
    Publication date: October 31, 2024
    Inventors: Piero L. RUGGIERO, Kristin PATTERSON, Mark HATCHER, Jiping LIU, Uchenna H. ILOEJE, Abraham J. LANGSETH
  • Synthesis of nirogacestat
    Patent number: 12110277
    Abstract: The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: October 8, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • SYSTEMS AND METHODS FOR RESIDUAL LIMBS OF AMPUTEES
    Publication number: 20240325172
    Abstract: Various aspects of this disclosure relate to a prosthetic cover comprising an array of sensors, which transmit signals to an array of electrodes in a liner that fits over a residual limb of an amputee. Different interactions with the prosthetic cover cause different activation of the electrodes to transmit electrical current through different areas of the residual limb and modulate neurons differently within the residual limb. Various aspects of this disclosure also relate to a prosthetic liner with a substrate that includes electrodes for transcutaneous electrical nerve stimulation and/or electronic muscle stimulation for a residual limb.
    Type: Application
    Filed: June 10, 2024
    Publication date: October 3, 2024
    Applicant: JSG IP Ventures, LLC
    Inventors: Jordan T. Doles, Michael Young, Paul Goudreau, Troy Winsand, Mark Hatcher
  • DOSAGE FORMS OF MIRDAMETINIB
    Publication number: 20240307327
    Abstract: The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
    Type: Application
    Filed: March 18, 2024
    Publication date: September 19, 2024
    Inventors: Piero L. RUGGIERO, Kristin PATTERSON, Mark HATCHER, Jiping LIU, Uchenna H. Iloeje, Abraham J. Langseth
  • DOSAGE FORMS OF MIRDAMETINIB
    Publication number: 20240307326
    Abstract: The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
    Type: Application
    Filed: March 18, 2024
    Publication date: September 19, 2024
    Inventors: Piero L. RUGGIERO, Kristin PATTERSON, Mark HATCHER, Jiping LIU, Uchenna H. ILOEJE, Abraham J. LANGSETH
  • SYSTEMS AND METHODS FOR RESIDUAL LIMBS OF AMPUTEES
    Publication number: 20240252327
    Abstract: Various aspects of this disclosure relate to a prosthetic cover comprising an array of sensors, which transmit signals to an array of electrodes in a liner that fits over a residual limb of an amputee. Different interactions with the prosthetic cover cause different activation of the electrodes to transmit electrical current through different areas of the residual limb and modulate neurons differently within the residual limb. Various aspects of this disclosure also relate to a prosthetic liner with a substrate that includes electrodes for transcutaneous electrical nerve stimulation and/or electronic muscle stimulation for a residual limb.
    Type: Application
    Filed: April 8, 2024
    Publication date: August 1, 2024
    Applicant: NeuroX Innovations Inc.
    Inventors: Jordan T. Doles, Michael Young, Paul Goudreau, Troy Winsand, Mark Hatcher
  • Dosage forms of mirdametinib
    Patent number: 12029711
    Abstract: The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
    Type: Grant
    Filed: March 18, 2024
    Date of Patent: July 9, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Piero L. Ruggiero, Kristin Patterson, Mark Hatcher, Jiping Liu, Uchenna H. Iloeje, Abraham J. Langseth
  • CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240217937
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Application
    Filed: September 8, 2022
    Publication date: July 4, 2024
    Inventors: Kristin PATTERSON, Mark HATCHER
  • CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240058307
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 20, 2023
    Publication date: February 22, 2024
    Inventors: Kristin PATTERSON, Mark HATCHER
  • Chlorinated tetralin compounds and pharmaceutical compositions
    Patent number: 11844780
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: December 19, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • Chlorinated tetralin compounds and pharmaceutical compositions
    Patent number: 11807611
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • SYNTHESIS OF NIROGACESTAT
    Publication number: 20230312480
    Abstract: The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
    Type: Application
    Filed: April 20, 2023
    Publication date: October 5, 2023
    Inventors: Kristin PATTERSON, Mark HATCHER
  • CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230310379
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 5, 2023
    Inventors: Kristin PATTERSON, Mark HATCHER
  • CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230250065
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Application
    Filed: April 17, 2023
    Publication date: August 10, 2023
    Inventors: Kristin PATTERSON, Mark HATCHER
  • Chlorinated tetralin compounds and pharmaceutical compositions
    Patent number: 11612588
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: March 28, 2023
    Assignee: Spring Works Therapeutics, Inc.
    Inventors: Kristin Patterson, Mark Hatcher
  • CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230091097
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 19, 2022
    Publication date: March 23, 2023
    Inventors: Kristin PATTERSON, Mark HATCHER
  • CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230090557
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 4, 2022
    Publication date: March 23, 2023
    Inventors: Kristin PATTERSON, Mark HATCHER